RTRX - Retrophin, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.18
+0.16 (+1.37%)
As of 11:46AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close12.01
Open12.01
Bid12.28 x 1100
Ask12.33 x 800
Day's Range11.99 - 12.35
52 Week Range11.39 - 29.70
Volume112,206
Avg. Volume684,803
Market Cap522.967M
Beta (3Y Monthly)0.93
PE Ratio (TTM)N/A
EPS (TTM)-3.42
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.00
Trade prices are not sourced from all markets
  • Biotech Stock Roundup: AMGN to Buy CELG's Otezla, ALXN's Soliris Gets EC Nod & More
    Zacks

    Biotech Stock Roundup: AMGN to Buy CELG's Otezla, ALXN's Soliris Gets EC Nod & More

    Key highlights of the past week include drug approvals, and other regulatory and pipeline news.

  • Retrophin Down on Neurological Disorder Drug Study Failure
    Zacks

    Retrophin Down on Neurological Disorder Drug Study Failure

    Retrophin (RTRX) declines as the late-stage study on a rare neurological disorder candidate failed to achieve its main goal.

  • Why Tilray, Splunk, and Retrophin Slumped Today
    Motley Fool

    Why Tilray, Splunk, and Retrophin Slumped Today

    Find out how earnings and other factors hit these stocks.

  • A Risky Drug Didn't Pan Out For This Biotech — Shares Hit 3-Year Low
    Investor's Business Daily

    A Risky Drug Didn't Pan Out For This Biotech — Shares Hit 3-Year Low

    Retrophin stock collapsed to a three-year low Thursday after the biotech company's treatment for a rare nervous system disease failed in a Phase 3 test. The drug missed two key goals.

  • Why Retrophin, Inc. Is Tanking Today
    Motley Fool

    Why Retrophin, Inc. Is Tanking Today

    Retrophin's PKAN drug candidate missed the mark in a late-stage trial.

  • Shkreli-Founded Biotech Seen Ripe for Buying as Shares Tumble
    Bloomberg

    Shkreli-Founded Biotech Seen Ripe for Buying as Shares Tumble

    (Bloomberg) -- Retrophin Inc. shares plummeted as much as 32% in early trading on Thursday after an experimental therapy from the drugmaker missed the main and key secondary goals in a late-stage study. That may signal an opportunity to pick up shares, according to one analyst.“Selloff overdone, buy,” Nomura Instinet’s Christopher Marai advised clients as the stock tumbled below $12 a share. All the sell-side analysts tracked by Bloomberg rate the company the equivalent of a buy. Marai is among the most bullish with a Street high 12-month price target of $57.The biotech -- founded by Martin Shkreli, the jailed “pharma bro” who was convicted in 2017 for defrauding investors -- had its biggest intraday drop since February 2013. Fosmetpantotenate failed to work any better than placebo in a rare neurological disease known as pantothenate kinase-associated neurodegeneration or PKAN.“This program has not represented substantial valuation in RTRX shares, given its speculative nature,” Marai said. Retrophin has $10 a share in cash and with a base business of $180 million for 2019, data for another key drug -- sparsentan -- accounts for another $14 of Marai’s price target.Retrophin is studying sparsentan in two diseases linked to end-stage kidney disease. The company said in a statement that it was focused on advancing these programs. While U.S. and European regulators have granted sparsentan orphan drug status, those results are not expected until 2021.To contact the reporter on this story: Cristin Flanagan in New York at cflanagan1@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Morwenna ConiamFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • MarketWatch

    Retrophin's stock plunges after late-stage trial for PKAN treatment fails to meet targets

    Shares of Retrophin Inc. plunged 26% toward a 3 1/2-year low in premarket trading Thursday, after the biopharmaceutical company said a phase 3 trial of its treatment for pantothenate kinase-associated neurodegeneration failed to meet its primary and secondary endpoints. Pantothenate kinase-associated neurodegeneration (PKAN) is a rare, genetic and life-threatening neurological disorder. "We are very disappointed in the topline results from the FORT Study, particularly because we have seen the devastating impact of PKAN on patients and their families, and a significant unmet need remains with no approved treatment option," said Chief Executive Eric Dube. "We will work closely with the investigators to further analyze the results of the study and share them with the PKAN community to contribute to the growing knowledge of this rare disorder." The company said it remains focused on advancing its two phase 3 programs evaluation its treatment of focal segmental glomerulosclerosis (FSGS) and IgA nephropathy. The stock has lost 23.1% year to date through Wednesday, while the iShares Nasdaq Biotechnology ETF has gained 10.0% and the S&P 500 has advanced 16.7%.

  • Benzinga

    The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 21) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arrowhead ...

  • Reuters

    CORRECTED-UPDATE 2-Retrophin scraps nervous system disorder study, shares dive

    Retrophin Inc said on Thursday it was discontinuing the late-stage study for its rare neurological disorder treatment after it failed to improve patients' ability to conduct daily activities such as eating and walking, sending shares down 30%. The treatment, fosmetpantotenate, was being tested against placebo in 84 patients with pantothenate kinase-associated neurodegeneration (PKAN), a rare, genetic and life-threatening disorder. "We have realized that this is a failed study with no difference to placebo," Chief Executive Officer Eric Dube said.

  • GlobeNewswire

    Retrophin Announces Topline Results from Phase 3 FORT Study of Fosmetpantotenate in Patients with PKAN

    Retrophin, Inc. (RTRX) today announced that the Phase 3 FORT Study evaluating the safety and efficacy of fosmetpantotenate compared to placebo in patients with pantothenate kinase-associated neurodegeneration (PKAN) did not meet its primary endpoint and did not demonstrate a difference between treatment groups. “We are very disappointed in the topline results from the FORT Study, particularly because we have seen the devastating impact of PKAN on patients and their families, and a significant unmet need remains with no approved treatment option.

  • Implied Volatility Surging for Retrophin (RTRX) Stock Options
    Zacks

    Implied Volatility Surging for Retrophin (RTRX) Stock Options

    Investors need to pay close attention to Retrophin (RTRX) stock based on the movements in the options market lately.

  • Thomson Reuters StreetEvents

    Edited Transcript of RTRX earnings conference call or presentation 6-Aug-19 8:30pm GMT

    Q2 2019 Retrophin Inc Earnings Call

  • Retrophin (RTRX) Q2 2019 Earnings Call Transcript
    Motley Fool

    Retrophin (RTRX) Q2 2019 Earnings Call Transcript

    RTRX earnings call for the period ending June 30, 2019.

  • Retrophin (RTRX) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Retrophin (RTRX) Reports Q2 Loss, Tops Revenue Estimates

    Retrophin (RTRX) delivered earnings and revenue surprises of -48.72% and 4.79%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Retrophin to Present at Canaccord Genuity’s 39th Annual Growth Conference

    SAN DIEGO, July 31, 2019 -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the Canaccord Genuity 39th Annual.

  • Is Retrophin (NASDAQ:RTRX) A Risky Investment?
    Simply Wall St.

    Is Retrophin (NASDAQ:RTRX) A Risky Investment?

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • Analysts Estimate Retrophin (RTRX) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Retrophin (RTRX) to Report a Decline in Earnings: What to Look Out for

    Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Retrophin to Report Second Quarter 2019 Financial Results

    SAN DIEGO, July 23, 2019 -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report second quarter 2019 financial results on Tuesday, August 6, 2019 after the close of.

  • Benzinga

    The Week Ahead In Biotech: Pending Clinical Readouts In Focus

    Biotech stocks headed south last week, reversing decent gains made in the previous week. Unfavorable FDA decisions, botched trials and weaker broader market sentiment all weighed down on the sector. Here ...

  • U.S. court urged to throw out 'Pharma Bro' Martin Shkreli's conviction
    Reuters

    U.S. court urged to throw out 'Pharma Bro' Martin Shkreli's conviction

    A lawyer for former pharmaceutical executive Martin Shkreli on Friday urged a federal appeals court to overturn Shkreli's criminal conviction for defrauding investors in hedge funds he founded. The lawyer, Mark Baker, argued that the jury that convicted Shkreli was given incorrect instructions about securities fraud. Baker faced a barrage of skeptical questions from a three-judge panel during a brief proceeding in the 2nd U.S. Circuit Court of Appeals in Manhattan.

  • An Intrinsic Calculation For Retrophin, Inc. (NASDAQ:RTRX) Suggests It's 36% Undervalued
    Simply Wall St.

    An Intrinsic Calculation For Retrophin, Inc. (NASDAQ:RTRX) Suggests It's 36% Undervalued

    How far off is Retrophin, Inc. (NASDAQ:RTRX) from its intrinsic value? Using the most recent financial data, we'll...

  • Is Retrophin, Inc. (NASDAQ:RTRX) Trading At A 36% Discount?
    Simply Wall St.

    Is Retrophin, Inc. (NASDAQ:RTRX) Trading At A 36% Discount?

    In this article we are going to estimate the intrinsic value of Retrophin, Inc. (NASDAQ:RTRX) by taking the expected...

  • Shkreli and Retrophin resolve 'all outstanding disputes'
    American City Business Journals

    Shkreli and Retrophin resolve 'all outstanding disputes'

    A Retrophin spokeswoman confirmed Thursday that the settlement covers Shkreli’s $30 million lawsuit from last month.